{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:59:34Z","timestamp":1794257974799,"version":"4.9.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872371"],"award-info":[{"award-number":["81872371"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Project Program of State Key Laboratory of Molecular Oncology","award":["SKL-KF-2019-11"],"award-info":[{"award-number":["SKL-KF-2019-11"]}]},{"name":"Natural Science Foundation of the Higher Education Institutions of Anhui Province","award":["KJ2018A0248"],"award-info":[{"award-number":["KJ2018A0248"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metabolic reprogramming contributes significantly to tumor development and is tightly linked to drug resistance. The chemotherapeutic agent etoposide (VP-16) has been used clinically in the treatment of lung cancer but possess different sensitivity and efficacy towards SCLC and NSCLC. Here, we assessed the impact of etoposide on glycolytic metabolism in SCLC and NSCLC cell lines and investigated the role of metabolic rewiring in mediating etoposide resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>glycolytic differences of drug-treated cancer cells were determined by extracellular acidification rate (ECAR), glucose consumption, lactate production and western blot. DNA damage was evaluated by the comet assay and western blot. Chemoresistant cancer cells were analyzed by viability, apoptosis and western blot. Chromatin immunoprecipitation (ChIP) was used for analysis of DNA-protein interaction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Here we showed that exposure to chemotherapeutic drug etoposide induces an exacerbation of ROS production which activates HIF-1\u03b1-mediated the metabolic reprogramming toward increased glycolysis and lactate production in non-small cell lung cancer (NSCLC). We identified lactic acidosis as the key that confers multidrug resistance through upregulation of multidrug resistance-associated protein 1 (MRP1, encoded by <jats:italic>ABCC1<\/jats:italic>), a member of ATP-binding cassette (ABC) transporter family. Mechanistically, lactic acid coordinates TGF-\u03b21\/Snail and TAZ\/AP-1 pathway to induce formation of Snail\/TAZ\/AP-1 complex at the MRP1\/ABCC1 promoter. Induction of MRP1 expression inhibits genotoxic and apoptotic effects of chemotherapeutic drugs by increasing drug efflux. Furthermore, titration of lactic acid with NaHCO<jats:sub>3<\/jats:sub> was sufficient to overcome resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The chemotherapeutic drug etoposide induces the shift toward aerobic glycolysis in the NSCLC rather than SCLC cell lines. The increased lactic acid in extracellular environment plays important role in etoposide resistance through upregulation of MRP expression. These data provide first evidence for the increased lactate production, upon drug treatment, contributes to adaptive resistance in NSCLC and reveal potential vulnerabilities of lactate metabolism and\/or pathway suitable for therapeutic targeting.<\/jats:p>\n                \n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12964-020-00653-3","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T06:03:02Z","timestamp":1603432982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells"],"prefix":"10.1186","volume":"18","author":[{"given":"Qi","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenkang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haodong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenkai","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuantao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianke","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiguang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"issue":"2","key":"653_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1753465815617871","volume":"10","author":"M Shea","year":"2016","unstructured":"Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016;10(2):113\u201329.","journal-title":"Ther Adv Respir Dis"},{"issue":"2","key":"653_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1758834014567470","volume":"7","author":"R Sundar","year":"2015","unstructured":"Sundar R, et al. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):85\u201396.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"653_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275\u201387.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"653_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00109-010-0623-4","volume":"88","author":"K Daskalow","year":"2010","unstructured":"Daskalow K, et al. Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. J Mol Med (Berl). 2010;88(8):817\u201327.","journal-title":"J Mol Med (Berl)"},{"issue":"6","key":"653_CR5","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-08-1090","volume":"8","author":"R Sullivan","year":"2009","unstructured":"Sullivan R, Graham CH. Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Ther. 2009;8(6):1702\u201313.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"653_CR6","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.cmet.2018.08.006","volume":"28","author":"M Apicella","year":"2018","unstructured":"Apicella M, et al. Increased lactate secretion by Cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies. Cell Metab. 2018;28(6):848\u201365 e6.","journal-title":"Cell Metab"},{"issue":"21","key":"653_CR7","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1158\/1078-0432.CCR-08-0957","volume":"14","author":"K Yonesaka","year":"2008","unstructured":"Yonesaka K, et al. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 2008;14(21):6963\u201373.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"653_CR8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of Cancer metabolism. Cell Metab. 2016;23(1):27\u201347.","journal-title":"Cell Metab"},{"key":"653_CR9","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.60","volume":"4","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013;4:e532.","journal-title":"Cell Death Dis"},{"issue":"4","key":"653_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/metabo5040571","volume":"5","author":"M Rahman","year":"2015","unstructured":"Rahman M, Hasan MR. Cancer metabolism and drug resistance. Metabolites. 2015;5(4):571\u2013600.","journal-title":"Metabolites"},{"issue":"1","key":"653_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13046-018-0701-y","volume":"37","author":"X Li","year":"2018","unstructured":"Li X, et al. Upregulation of lactate-inducible snail protein suppresses oncogene-mediated senescence through p16(INK4a) inactivation. J Exp Clin Cancer Res. 2018;37(1):39.","journal-title":"J Exp Clin Cancer Res"},{"key":"653_CR12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2741\/4368","volume":"20","author":"M Gallo","year":"2015","unstructured":"Gallo M, et al. Lactic dehydrogenase and cancer: an overview. Front Biosci (Landmark Ed). 2015;20:1234\u201349.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"42","key":"653_CR13","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1038\/onc.2017.188","volume":"36","author":"J Feng","year":"2017","unstructured":"Feng J, et al. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Oncogene. 2017;36(42):5829\u201339.","journal-title":"Oncogene"},{"issue":"2","key":"653_CR14","first-page":"119","volume":"38","author":"I San-Millan","year":"2017","unstructured":"San-Millan I, Brooks GA. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg effect. Carcinogenesis. 2017;38(2):119\u201333.","journal-title":"Carcinogenesis"},{"issue":"2","key":"653_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2017.09.019","volume":"171","author":"B Faubert","year":"2017","unstructured":"Faubert B, et al. Lactate metabolism in human lung tumors. Cell. 2017;171(2):358\u201371 e9.","journal-title":"Cell"},{"issue":"43","key":"653_CR16","doi-asserted-by":"publisher","first-page":"70898","DOI":"10.18632\/oncotarget.12286","volume":"7","author":"YJ Lee","year":"2016","unstructured":"Lee YJ, et al. G-protein-coupled receptor 81 promotes a malignant phenotype in breast cancer through angiogenic factor secretion. Oncotarget. 2016;7(43):70898\u2013911.","journal-title":"Oncotarget"},{"issue":"1","key":"653_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jdsr.2017.08.003","volume":"54","author":"Y Kato","year":"2018","unstructured":"Kato Y, et al. Cancer metabolism: new insights into classic characteristics. Jpn Dent Sci Rev. 2018;54(1):8\u201321.","journal-title":"Jpn Dent Sci Rev"},{"key":"653_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-3-319-24223-1_10","volume":"893","author":"ES Kim","year":"2016","unstructured":"Kim ES. Chemotherapy resistance in lung Cancer. Adv Exp Med Biol. 2016;893:189\u2013209.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"653_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/cas.14246","volume":"111","author":"T Huang","year":"2020","unstructured":"Huang T, et al. Lactate-fueled oxidative metabolism drives DNA methyltransferase 1-mediated transcriptional co-activator with PDZ binding domain protein activation. Cancer Sci. 2020;111(1):186\u201399.","journal-title":"Cancer Sci"},{"issue":"5","key":"653_CR20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, et al. LDHA-associated lactic acid production blunts tumor Immunosurveillance by T and NK cells. Cell Metab. 2016;24(5):657\u201371.","journal-title":"Cell Metab"},{"issue":"11","key":"653_CR21","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","volume":"72","author":"A Calcinotto","year":"2012","unstructured":"Calcinotto A, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012;72(11):2746\u201356.","journal-title":"Cancer Res"},{"issue":"9","key":"653_CR22","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer K, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109(9):3812\u20139.","journal-title":"Blood"},{"issue":"16","key":"653_CR23","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1101\/gad.1815309","volume":"23","author":"H Jiang","year":"2009","unstructured":"Jiang H, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009;23(16):1895\u2013909.","journal-title":"Genes Dev"},{"issue":"1","key":"653_CR24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41467-019-14262-3","volume":"11","author":"C Corbet","year":"2020","unstructured":"Corbet C, et al. TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 2020;11(1):454.","journal-title":"Nat Commun"},{"key":"653_CR25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-pharmtox-011613-135959","volume":"54","author":"SP Cole","year":"2014","unstructured":"Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol. 2014;54:95\u2013117.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"653_CR26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0360-3016(02)03037-7","volume":"54","author":"S Henness","year":"2002","unstructured":"Henness S, et al. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression. Int J Radiat Oncol Biol Phys. 2002;54(3):895\u2013902.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"653_CR27","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.febslet.2005.12.036","volume":"580","author":"RG Deeley","year":"2006","unstructured":"Deeley RG, Cole SP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 2006;580(4):1103\u201311.","journal-title":"FEBS Lett"},{"issue":"9","key":"653_CR28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/ncb3394","volume":"18","author":"Y Tang","year":"2016","unstructured":"Tang Y, et al. Snail\/slug binding interactions with YAP\/TAZ control skeletal stem cell self-renewal and differentiation. Nat Cell Biol. 2016;18(9):917\u201329.","journal-title":"Nat Cell Biol"},{"issue":"9","key":"653_CR29","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/ncb3216","volume":"17","author":"F Zanconato","year":"2015","unstructured":"Zanconato F, et al. Genome-wide association between YAP\/TAZ\/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 2015;17(9):1218\u201327.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"653_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2169\/internalmedicine.41.79","volume":"41","author":"GL Semenza","year":"2002","unstructured":"Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med. 2002;41(2):79\u201383.","journal-title":"Intern Med"},{"issue":"6","key":"653_CR31","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.bbadis.2012.02.004","volume":"1822","author":"L Guo","year":"2012","unstructured":"Guo L, et al. Mitochondrial reactive oxygen species mediates nicotine-induced hypoxia-inducible factor-1alpha expression in human non-small cell lung cancer cells. Biochim Biophys Acta. 2012;1822(6):852\u201361.","journal-title":"Biochim Biophys Acta"},{"key":"653_CR32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2147\/DDDT.S92687","volume":"10","author":"MA Papiez","year":"2016","unstructured":"Papiez MA, et al. Curcumin enhances the cytogenotoxic effect of etoposide in leukemia cells through induction of reactive oxygen species. Drug Des Devel Ther. 2016;10:557\u201370.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"653_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/jnci\/84.2.113","volume":"84","author":"K Kasahara","year":"1992","unstructured":"Kasahara K, et al. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst. 1992;84(2):113\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"653_CR34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s002800050559","volume":"39","author":"K Yamazaki","year":"1997","unstructured":"Yamazaki K, et al. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Cancer Chemother Pharmacol. 1997;39(3):192\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"653_CR35","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/annonc\/mdw321","volume":"27","author":"KA Olaussen","year":"2016","unstructured":"Olaussen KA, Postel-Vinay S. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Ann Oncol. 2016;27(11):2004\u201316.","journal-title":"Ann Oncol"},{"issue":"3","key":"653_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.drup.2011.03.001","volume":"14","author":"N Rohwer","year":"2011","unstructured":"Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011;14(3):191\u2013201.","journal-title":"Drug Resist Updat"},{"issue":"6","key":"653_CR37","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2217\/14796694.1.6.779","volume":"1","author":"A De Milito","year":"2005","unstructured":"De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 2005;1(6):779\u201386.","journal-title":"Future Oncol"},{"issue":"16","key":"653_CR38","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41388-020-1216-5","volume":"39","author":"TP Brown","year":"2020","unstructured":"Brown TP, et al. The lactate receptor GPR81 promotes breast cancer growth via a paracrine mechanism involving antigen-presenting cells in the tumor microenvironment. Oncogene. 2020;39(16):3292\u2013304.","journal-title":"Oncogene"},{"issue":"1","key":"653_CR39","doi-asserted-by":"publisher","first-page":"165576","DOI":"10.1016\/j.bbadis.2019.165576","volume":"2020","author":"Q Xie","year":"1866","unstructured":"Xie Q, et al. A lactate-induced snail\/STAT3 pathway drives GPR81 expression in lung cancer cells. Biochim Biophys Acta Mol basis Dis. 1866;2020(1):165576.","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"issue":"4","key":"653_CR40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.cell.2015.12.034","volume":"164","author":"CT Hensley","year":"2016","unstructured":"Hensley CT, et al. Metabolic heterogeneity in human lung tumors. Cell. 2016;164(4):681\u201394.","journal-title":"Cell"},{"issue":"2","key":"653_CR41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00280-013-2366-8","volume":"73","author":"EJ Sullivan","year":"2014","unstructured":"Sullivan EJ, et al. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemother Pharmacol. 2014;73(2):417\u201327.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"30","key":"653_CR42","doi-asserted-by":"crossref","first-page":"49275","DOI":"10.18632\/oncotarget.17568","volume":"8","author":"M Wangpaichitr","year":"2017","unstructured":"Wangpaichitr M, et al. Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer. Oncotarget. 2017;8(30):49275\u201392.","journal-title":"Oncotarget"},{"issue":"16","key":"653_CR43","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1158\/0008-5472.CAN-16-2874","volume":"77","author":"SC Tripathi","year":"2017","unstructured":"Tripathi SC, et al. MCAM mediates Chemoresistance in small-cell lung Cancer via the PI3K\/AKT\/SOX2 signaling pathway. Cancer Res. 2017;77(16):4414\u201325.","journal-title":"Cancer Res"},{"issue":"4","key":"653_CR44","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey KF, Zhang X, Thomas DM. The hippo pathway and human cancer. Nat Rev Cancer. 2013;13(4):246\u201357.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"653_CR45","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/(SICI)1097-0215(19960611)66:6<760::AID-IJC9>3.0.CO;2-Y","volume":"66","author":"G Giaccone","year":"1996","unstructured":"Giaccone G, et al. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int J Cancer. 1996;66(6):760\u20137.","journal-title":"Int J Cancer"},{"issue":"5","key":"653_CR46","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/1535-7163.MCT-07-2088","volume":"7","author":"T Oguri","year":"2008","unstructured":"Oguri T, et al. MRP7\/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther. 2008;7(5):1150\u20135.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"653_CR47","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/bjc.1995.372","volume":"72","author":"E Ota","year":"1995","unstructured":"Ota E, et al. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer. 1995;72(3):550\u20134.","journal-title":"Br J Cancer"},{"issue":"6","key":"653_CR48","first-page":"1798","volume":"7","author":"LC Young","year":"2001","unstructured":"Young LC, et al. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 2001;7(6):1798\u2013804.","journal-title":"Clin Cancer Res"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-020-00653-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-020-00653-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-020-00653-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T19:40:38Z","timestamp":1634931638000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-020-00653-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1186\/s12964-020-00653-3","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.21203\/rs.3.rs-107376\/v1","asserted-by":"subject"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"assertion":[{"value":"19 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}